Genprex, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY September 30, 2022 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — |
| Operating income | -$15.5M | -$21.2M | -$31.1M | -$23.8M | — |
| Cash from operations | -$15.3M | -$17.9M | -$24.7M | -$17.6M | — |
| Capital expenditure | — | — | — | $0 | — |
| Free cash flow | — | — | — | -$17.6M | — |
| Impairments | $0 | $0 | $0 | $0 | — |
| Total assets | $10.2M | $4.1M | $10.7M | $25.1M | $29.9M |
| Total liabilities | $2.2M | $2.5M | — | — | $2.5M |
Shares outstanding 10.6M · Free float 62.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.